For the quarter ended December 2025, Chemours (CC) reported revenue of $1.33 billion, down 2.2% over the same period last year. EPS came in at $0.05, compared to $0.11 in the year-ago quarter.
The reported revenue represents no surprise over the Zacks Consensus Estimate of $1.33 billion. With the consensus EPS estimate being $0, the EPS surprise was +2400%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Chemours performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:- Revenues- Other Segment: $12 million versus the four-analyst average estimate of $12.65 million. The reported number represents a year-over-year change of -7.7%.
- Revenues- Titanium Technologies: $561 million compared to the $548.65 million average estimate based on four analysts. The reported number represents a change of -11.2% year over year.
- Revenues- Advanced Performance Materials: $312 million versus $302.82 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -3.7% change.
- Revenues- Thermal & Specialized Solutions: $444 million versus $447.37 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +13.9% change.
- Adjusted EBITDA- Titanium Technologies: $23 million versus $17.47 million estimated by four analysts on average.
- Adjusted EBITDA- Other Segment: $1 million compared to the $0.87 million average estimate based on four analysts.
- Adjusted EBITDA- Advanced Performance Materials: $12 million versus $34.36 million estimated by four analysts on average.
- Adjusted EBITDA- Thermal & Specialized Solutions: $128 million compared to the $135.12 million average estimate based on four analysts.
View all Key Company Metrics for Chemours here>>>
Shares of Chemours have returned +30.6% over the past month versus the Zacks S&P 500 composite's -0.8% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpThe Chemours Company (CC) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
